Human in vitro models of nonalcoholic fatty liver disease
Open accessAbstract
Systems-oriented approaches involving integrated in vitro and in silico models are emerging as a basis for future risk assessment strategies to address the current challenge in chemical risk assessment of increased numbers of registered chemicals with no toxicological data. Liver toxicity poses a major concern in risk assessment as the liver is exposed to most xenobiotic compounds and their bioactive metabolites, making the liver susceptible to chemically induced liver diseases. Nonalcoholic fatty liver disease (NAFLD) is a rising global burden with an estimated prevalence of about 25% in the general population. Risk factors for NAFLD include metabolic disorders, genetics, drugs, and environmental exposures. To integrate in vitro data into computational models and use in vitro to in vivo extrapolation to systematically assess the risk of chemicals to induce NAFLD, sophisticated human cell models are needed. Reviewed here are characteristics and limitations of 2D and 3D monoculture and coculture human liver cell models, including microphysiological systems, in which NAFLD-relevant end points were addressed together with their results. The aim of this review is to inform selection of experimental test systems depending on the toxicological question to be addressed and to promote the further development of in vitro approaches that address existing technological gaps.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
To induce steatosis in HepG2, supraphysiological concentrations of FFAs (0.5-2.0 mM) are often used.
“Second, to induce steatosis, supraphysiological concentrations of FFAs (concentrations of 0.5–2.0 mM) are often used in HepG2 experiments [28,91,125,126,127,128,129,130].”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [28]
In subsequent studies, in vitro modeling of liver steatosis in HepG2 was performed by incubating cells with a mixture of free fatty acids, most often OA and PA, in a molar ratio of 1:1 or 2:1, at a total concentration of 0.5 to 1 mM, for 24-48 h.
“In subsequent studies, in vitro modeling of liver steatosis in the HepG2 cell line was performed by incubating cells with a mixture of free fatty acids, most often OA and PA, in a molar ratio of 1:1 or 2:1, at a total concentration of 0.5 to 1 mM, for 24–48 h [28,125].”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [28]
In 2D monocultures, FFA concentrations of 0.5-2.0 mM are more commonly used, which are higher than physiological values; this is a widely accepted compromise that allows for steatosis to be induced in a short amount of time (24-48 h).
“In 2D monocultures, concentrations of 0.5–2.0 mM are more commonly used, which are higher than physiological values [28,125,126,127,128]. This is a widely accepted compromise that allows for steatosis to be induced in a short amount of time (24–48 h).”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [28]
The citation lists haven’t been fetched yet
References 53 · Cited by 118
- Authors
- Müller, F. A., & Sturla, S. J.
- Affiliations
- ETH Zurich (CH)
- Corresponding author
- Sturla, Shana J.
- Venue
- Current Opinion in Toxicology
- Publisher
- Elsevier BV
- Published
- 2019-08
- Volume
- 16
- Pages
- 9-16
- ISSN
- 2468-2020 (ISSN-L)
- OpenAlex
- W2921906624
- Cited by
- 118
- References
- 53
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 24 · 2023: 18 · 2022: 20 · 2021: 21 · 2020: 8 · 2019: 2
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Current Opinion in Toxicology (publishedVersion, cc-by-nc-nd)
- Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by-nc-nd)
- ETH Zürich Research Collection
- Funders
- Horizon 2020
- Bundesamt für Lebensmittelsicherheit und Veterinärwesen
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Keywords
- non-alcoholic fatty liver disease, in vitro liver models, co-culture model, microphysiological systems, in vitro-in vivo extrapolation, chemical risk assessment, hepatotoxicity, 3D liver model, xenobiotic metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review